# Why Marijuana Could Be Reclassified as a Safer Drug Soon > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-federal-rescheduling-impact-research-policy/ > **Published:** 2026-04-23T01:06:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:14:45-04:00 > **Clinical Summary:** Explore the marijuana federal rescheduling impact on research, clinical trials, and policy changes that could reshape medical cannabis use and regulation. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyResearchFederal Regulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)[Clinical Trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Why This Matters Federal rescheduling would fundamentally alter the research landscape, potentially enabling higher-quality [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and standardized dosing studies that have been severely limited under Schedule I restrictions. This regulatory shift could also influence prescribing patterns and insurance coverage considerations for cannabis-based therapeutics. Clinical Summary The potential reclassification of cannabis from Schedule I to a lower controlled substance category would acknowledge its accepted medical use and lower abuse potential relative to substances like heroin or LSD. Schedule I classification has historically restricted [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) to observational studies and limited interventional trials, constraining evidence generation for specific medical conditions. Rescheduling would align federal policy with existing state [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs and could facilitate FDA-regulated product development. Dr. Caplan’s Take “This would be the single most impactful regulatory change for [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in decades, potentially unlocking the robust [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) we desperately need. However, rescheduling alone won’t immediately solve dosing standardization or product quality issues that patients face today.” Clinical Perspective 🧠 Clinicians should prepare for expanded research opportunities and potential changes in institutional policies regarding cannabis recommendations. Patient counseling should emphasize that rescheduling doesn’t immediately change product availability, quality standards, or evidence-based dosing protocols. Monitor for evolving institutional guidelines and research opportunities in your therapeutic areas of interest. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Marijuana%20Could%20Be%20Reclassified%20As%20A%20Safer%20Drug%20Soon%E2%80%94Here%27s%20Why%20-%20Forbes%20%40drcaplan&url=https%3A//www.forbes.com/sites/zacharyfolk/2026/04/22/trumps-justice-department-could-reclassify-marijuana-as-a-safer-drug-wednesday/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.forbes.com/sites/zacharyfolk/2026/04/22/trumps-justice-department-could-reclassify-marijuana-as-a-safer-drug-wednesday/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Marijuana%20Could%20Be%20Reclassified%20As%20A%20Safer%20Drug%20Soon%E2%80%94Here%27s%20Why%20-%20Forbes%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.forbes.com/sites/zacharyfolk/2026/04/22/trumps-justice-department-could-reclassify-marijuana-as-a-safer-drug-wednesday/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.forbes.com/sites/zacharyfolk/2026/04/22/trumps-justice-department-could-reclassify-marijuana-as-a-safer-drug-wednesday/](https://www.forbes.com/sites/zacharyfolk/2026/04/22/trumps-justice-department-could-reclassify-marijuana-as-a-safer-drug-wednesday/) Table of Contents - [FAQ](#FAQ)[What is the CED Clinical Relevance rating system?](#What_is_the_CED_Clinical_Relevance_rating_system) - [What topics does this cannabis news article cover?](#What_topics_does_this_cannabis_news_article_cover) - [Why is this article marked as having “Notable Clinical Interest”?](#Why_is_this_article_marked_as_having_8220Notable_Clinical_Interest8221) - [What is the source of this cannabis news?](#What_is_the_source_of_this_cannabis_news) - [How should healthcare professionals use this information?](#How_should_healthcare_professionals_use_this_information) - [Related](#Related) ## FAQ #### What is the CED Clinical Relevance rating system? The CED Clinical Relevance system appears to be a rating scale used to categorize medical cannabis news and developments. This article received a rating of #70, indicating “Notable Clinical Interest” for emerging findings or policy developments worth monitoring closely. #### What topics does this cannabis news article cover? Based on the tags, this article covers policy developments, research findings, federal regulation, and medical cannabis. It appears to focus on multiple aspects of cannabis-related healthcare and regulatory matters. #### Why is this article marked as having “Notable Clinical Interest”? The article is flagged for notable clinical interest because it contains emerging findings or policy developments in the cannabis field. These developments are considered worth monitoring closely by healthcare professionals and researchers. #### What is the source of this cannabis news? This news comes from CED Clinic, which appears to be a medical organization that tracks and analyzes cannabis-related clinical and policy developments. They provide clinical relevance ratings to help healthcare professionals prioritize important information. #### How should healthcare professionals use this information? Healthcare professionals should monitor these developments closely as they may impact clinical practice, [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/), or regulatory compliance. The “Notable Clinical Interest” designation suggests these are emerging trends that could influence future medical cannabis protocols or policies. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Marijuana MSOs surge on report Trump set to formally reclassify cannabis | Seeking Alpha](https://cedclinic.com/marijuana-federal-reclassification-2026-research-impact/) Learn how major marijuana companies are reacting to potential federal reclassification and what it means for the cannabis market. [Read More](https://cedclinic.com/marijuana-federal-reclassification-2026-research-impact/) [DOJ Expected to Ease Marijuana Controls as Soon as Wed. – YouTube](https://cedclinic.com/doj-marijuana-controls-easing-cannabis-research-update/) Watch the latest update on the Department of Justice's anticipated easing of marijuana restrictions and its implications. [Watch Now](https://cedclinic.com/doj-marijuana-controls-easing-cannabis-research-update/) [How U.S. marijuana reclassification could help cannabis companies – The Detroit News](https://cedclinic.com/federal-cannabis-reclassification-benefits/) Explore expert insights on how marijuana reclassification might benefit cannabis businesses and the broader industry. [Explore Insights](https://cedclinic.com/federal-cannabis-reclassification-benefits/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).